Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 1/2020

03.03.2020 | Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Food as Therapy for Frailty

verfasst von: Tariq Salim, Susan A. Stark, Andres Duarte-Rojo

Erschienen in: Current Hepatology Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Frailty in end-stage liver disease is a risk factor for mortality and other serious complications for transplant-waitlist patients. Multiple interventions have been studied to try to mitigate these effects by targeting contributors to frailty, most notably sarcopenia and hepatic encephalopathy. This review provides an evidence-based summary of interventions that have been recommended to prevent or reverse frailty and its contributors.

Recent Findings

Current nutritional recommendations for frailty in end-stage liver disease focus on mitigating the effects of ammonia toxicity, increased energy expenditure due to shifts in glucose metabolism, and micronutrient deficiency and supplementation.

Summary

Data regarding targeted nutritional interventions for frailty in cirrhosis are limited. Current evidence supports increasing caloric intake, increasing protein intake, avoiding a fasting state, branched-chain amino acid supplementation, screening for and treating vitamin D deficiency, and to a lesser extent l-carnitine supplementation. Future randomized controlled trials are necessary to validate these interventions as modifiers of frailty.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.PubMedCrossRef
2.
3.
Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates: frailty in liver transplant candidates. Am J Transplant. 2014;14:1870–9.PubMedPubMedCentralCrossRef
4.
Dunn MA, Josbeno DA, Tevar AD, Rachakonda V, Ganesh SR, Schmotzer AR, et al. Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. Am J Gastroenterol. 2016;111:1768–75.PubMedCrossRef
5.
• Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transplant. 2019;19:1896–906 An opinion statement released by experts in the field of frailty in end-stage liver disease advocating for the measurement of frailty in all liver transplant candidates using a standardized tool. Experts also advocated for the use of frailty to guide nutritional interventions and physical therapy, incorporating frailty in determining suitability for transplant, and future areas of research. PubMedPubMedCentral
6.
Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis: liver failure/cirrhosis/portal hypertension. Hepatology. 2015;62:584–90.PubMedCrossRef
7.
Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CMM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation: sarcopenia after liver transplantation. Liver Transpl. 2014;20:640–8.PubMedCrossRef
8.
Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271–8.PubMedPubMedCentralCrossRef
9.
Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl. 2017;23:625–33.PubMedPubMedCentralCrossRef
10.
Tapper EB, Derstine B, Baki J, Su GL. Bedside measures of frailty and cognitive function correlate with sarcopenia in patients with cirrhosis. Dig Dis Sci. 2019;64(12):3652–9.PubMedCrossRef
11.
Tapper EB, Konerman M, Murphy S, Sonnenday CJ. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. Am J Transplant. 2018;18:2566–70.PubMedPubMedCentralCrossRef
12.
Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66:564–74.PubMedCrossRef
13.
• Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36 Evidence-based guidelines for nutritional interventions in patients with hepatic encephalopathy. PubMedCrossRef
14.
• Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L, et al. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–93 Nutritional guidelines for patients with chronic liver disease. Presents evidence-based recommendations for patients with chronic liver disease, cirrhosis, and specific comorbidities such as hepatic encephalopathy, patients with concurrent bone disease, and critically ill cirrhotic patients. CrossRef
15.
Carey EJ, Lai JC, Sonnenday C, Tapper EB, Tandon P, Duarte-Rojo A, et al. A North American expert opinion statement on sarcopenia in liver transplantation. Hepatology. 2019;70(5):1816–29.PubMedCrossRef
16.
Greco AV, Mingrone G, Benedetti G, Capristo E, Tataranni PA, Gasbarrini G. Daily energy and substrate metabolism in patients with cirrhosis. Hepatology. 1998;27:346–50.PubMedCrossRef
17.
18.
Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2012;27:430–41.PubMedCrossRef
19.
Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CMM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–35.PubMedCrossRef
20.
Everhart JE, Lok AS, Kim H-Y, Morgan TR, Lindsay KL, Chung RT, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137:549–57.PubMedCrossRef
21.
Guo Y-J, Tian Z-B, Jiang N, Ding X-L, Mao T, Jing X. Effects of late evening snack on cirrhotic patients: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018;2018:9189062.PubMedPubMedCentralCrossRef
22.
Fukushima H, Miwa Y, Ida E, Kuriyama S, Toda K, Shimomura Y, et al. Nocturnal branched-chain amino acid administration improves protein metabolism in patients with liver cirrhosis: comparison with daytime administration. JPEN J Parenter Enteral Nutr. 2003;27:315–22.PubMedCrossRef
23.
Yamanaka-Okumura H, Nakamura T, Takeuchi H, Miyake H, Katayama T, Arai H, et al. Effect of late evening snack with rice ball on energy metabolism in liver cirrhosis. Eur J Clin Nutr. 2006;60:1067–72.PubMedCrossRef
24.
Nakaya Y, Okita K, Suzuki K, Moriwaki H, Kato A, Miwa Y, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007;23:113–20.PubMedCrossRef
25.
Korenaga K, Korenaga M, Uchida K, Yamasaki T, Sakaida I. Effects of a late evening snack combined with alpha-glucosidase inhibitor on liver cirrhosis. Hepatol Res. 2008;38:1087–97.PubMedCrossRef
26.
Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48:557–66.PubMedCrossRef
27.
Yamanaka-Okumura H, Nakamura T, Miyake H, Takeuchi H, Katayama T, Morine Y, et al. Effect of long-term late-evening snack on health-related quality of life in cirrhotic patients. Hepatol Res. 2010;40:470–6.PubMedCrossRef
28.
Hiraoka A, Michitaka K, Kiguchi D, Izumoto H, Ueki H, Kaneto M, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29:1416–23.PubMedCrossRef
29.
30.
Córdoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41:38–43.PubMedCrossRef
31.
Gheorghe L, Iacob R, Vădan R, Iacob S, Gheorghe C. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. Rom J Gastroenterol. 2005;14:231–8.PubMed
32.
Swart GR, van den Berg JW, van Vuure JK, Rietveld T, Wattimena DL, Frenkel M. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin Nutr. 1989;8:329–36.PubMedCrossRef
33.
Weber FL, Minco D, Fresard KM, Banwell JG. Effects of vegetable diets on nitrogen metabolism in cirrhotic subjects. Gastroenterology. 1985;89:538–44.PubMedCrossRef
34.
35.
Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303:E983–93.PubMedPubMedCentralCrossRef
36.
Chen H-W, Dunn MA. Muscle at risk: the multiple impacts of ammonia on sarcopenia and frailty in cirrhosis. Clin Transl Gastroenterol. 2016;7:e170.PubMedPubMedCentralCrossRef
37.
Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GAM, Thapaliya S, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015;61:2018–29.PubMedCrossRef
38.
Leenders M, van Loon LJC. Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev. 2011;69:675–89.PubMedCrossRef
39.
Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010;26:482–90.PubMedCrossRef
40.
Román E, Torrades MT, Nadal MJ, Cárdenas G, Nieto JC, Vidal S, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci. 2014;59:1966–75.PubMedCrossRef
41.
Les I, Doval E, García-Martínez R, Planas M, Cárdenas G, Gómez P, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106:1081–8.PubMedCrossRef
42.
Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev. 2003;2003:CD001939.
43.
Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;5:CD001939.PubMed
44.
Holeček M. Branched-chain amino acid supplementation in treatment of liver cirrhosis: updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation. Nutrition. 2017;41:80–5.PubMedCrossRef
45.
Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65.PubMedCrossRef
46.
Buonomo AR, Zappulo E, Scotto R, Pinchera B, Perruolo G, Formisano P, et al. Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. Int J Infect Dis. 2017;63:23–9.PubMedCrossRef
47.
Konstantakis C, Tselekouni P, Kalafateli M, Triantos C. Vitamin D deficiency in patients with liver cirrhosis. Ann Gastroenterol. 2016;29:297–306.PubMedPubMedCentral
48.
Kubesch A, Quenstedt L, Saleh M, Rüschenbaum S, Schwarzkopf K, Martinez Y, et al. Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: a prospective cohort study. PLoS One. 2018;13:e0207162.PubMedPubMedCentralCrossRef
49.
Yang F, Ren H, Gao Y, Zhu Y, Huang W. The value of severe vitamin D deficiency in predicting the mortality risk of patients with liver cirrhosis: a meta-analysis. Clin Res Hepatol Gastroenterol. 2019;43(6):722–9.PubMedCrossRef
50.
Kotlarczyk MP, Perera S, Ferchak MA, Nace DA, Resnick NM, Greenspan SL. Vitamin D deficiency is associated with functional decline and falls in frail elderly women despite supplementation. Osteoporos Int. 2017;28:1347–53.PubMedCrossRef
51.
Bruyère O, Cavalier E, Reginster J-Y. Vitamin D and osteosarcopenia: an update from epidemiological studies. Curr Opin Clin Nutr Metab Care. 2017;20:498–503.PubMedPubMedCentralCrossRef
52.
Hirschfeld HP, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int. 2017;28:2781–90.PubMedCrossRef
53.
Phu S, Bani Hassan E, Vogrin S, Kirk B, Duque G. Effect of denosumab on falls, muscle strength, and function in community-dwelling older adults. J Am Geriatr Soc. 2019;67(12):2660–1.PubMedCrossRef
54.
Remelli F, Vitali A, Zurlo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients. 2019;11:E2861.PubMedCrossRef
55.
56.
Shiraki M, Shimizu M, Moriwaki H, Okita K, Koike K. Carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients. Hepatol Res. 2017;47(4):321–327.
57.
de Sousa C, Leung NW, Chalmers RA, Peters TJ. Free and total carnitine and acylcarnitine content of plasma, urine, liver and muscle of alcoholics. Clin Sci. 1988;75:437–40.CrossRef
58.
Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, et al. L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun. 2018;2:906–18.PubMedPubMedCentralCrossRef
59.
Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun. 2019;3:348–55.PubMedPubMedCentralCrossRef
60.
Nakanishi H, Kurosaki M, Tsuchiya K, Nakakuki N, Takada H, Matsuda S, et al. L-carnitine reduces muscle cramps in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:1540–3.PubMedCrossRef
61.
Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis. 2013;28:193–9.PubMedCrossRef
62.
Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology. 1988;8:1605–9.PubMedCrossRef
63.
Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutiérrez T, Villegas-López FA, Méndez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013;12:74.PubMedPubMedCentralCrossRef
64.
Shen Y-C, Chang Y-H, Fang C-J, Lin Y-S. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J. 2019;18:34.PubMedPubMedCentralCrossRef
65.
Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080–90.PubMedCrossRef
66.
Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, et al. Screening for zinc deficiency in patients with cirrhosis: when should we start? Dig Dis Sci. 2015;60:3130–5.PubMedCrossRef
67.
Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology. 2019;70:1690–703.PubMedCrossRef
68.
Ticinesi A, Lauretani F, Milani C, Nouvenne A, Tana C, Del Rio D, et al. Aging gut microbiota at the cross-road between nutrition, physical frailty, and sarcopenia: is there a gut-muscle axis? Nutrients. 2017;9:E1303.PubMedCrossRef
69.
Casula EP, Bisiacchi PS, Corrias M, Schiff S, Merkel C, Amodio P, et al. Acute hyperammonaemia induces a sustained decrease in vigilance, which is modulated by caffeine. Metab Brain Dis. 2015;30:143–9.PubMedCrossRef
Metadaten
Titel
Food as Therapy for Frailty
verfasst von
Tariq Salim
Susan A. Stark
Andres Duarte-Rojo
Publikationsdatum
03.03.2020
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 1/2020
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-020-00509-x

Weitere Artikel der Ausgabe 1/2020

Current Hepatology Reports 1/2020 Zur Ausgabe

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Nutrition in Cholestatic Liver Disease

Fatty Liver Disease (V Ajmera, Section Editor)

Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH)

Portal Hypertension and Liver Transplantation (R Reddy, Section Editor)

Recurrent Disease After Liver Transplantation

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Nutrition Management in the Critically Ill Patient with Cirrhosis

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

The Role of Vascular Injury and Congestion in the Pathogenesis of Cirrhosis: the Congestive Escalator and the Parenchymal Extinction Sequence

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

What Diet Should I Recommend My Patient with Hepatic Encephalopathy?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise